JP2020527727A5 - - Google Patents

Download PDF

Info

Publication number
JP2020527727A5
JP2020527727A5 JP2020522785A JP2020522785A JP2020527727A5 JP 2020527727 A5 JP2020527727 A5 JP 2020527727A5 JP 2020522785 A JP2020522785 A JP 2020522785A JP 2020522785 A JP2020522785 A JP 2020522785A JP 2020527727 A5 JP2020527727 A5 JP 2020527727A5
Authority
JP
Japan
Prior art keywords
binding molecule
seq
diagnostic method
cell receptor
autonomously
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020522785A
Other languages
English (en)
Japanese (ja)
Other versions
JP7239575B2 (ja
JP2020527727A (ja
Filing date
Publication date
Priority claimed from EP18162666.4A external-priority patent/EP3424527A1/de
Application filed filed Critical
Publication of JP2020527727A publication Critical patent/JP2020527727A/ja
Publication of JP2020527727A5 publication Critical patent/JP2020527727A5/ja
Application granted granted Critical
Publication of JP7239575B2 publication Critical patent/JP7239575B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020522785A 2017-07-07 2018-07-05 サンプル中の自律的に活性なb細胞受容体または自律的に活性化されたb細胞受容体を認識する方法 Active JP7239575B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17001166.2 2017-07-07
EP17001167.0 2017-07-07
EP17001167 2017-07-07
EP17001166 2017-07-07
EP18162666.4 2018-03-19
EP18162666.4A EP3424527A1 (de) 2017-07-07 2018-03-19 Diagnostisches verfahren
PCT/EP2018/068316 WO2019008128A1 (de) 2017-07-07 2018-07-05 Diagnostisches verfahren

Publications (3)

Publication Number Publication Date
JP2020527727A JP2020527727A (ja) 2020-09-10
JP2020527727A5 true JP2020527727A5 (enExample) 2021-08-12
JP7239575B2 JP7239575B2 (ja) 2023-03-14

Family

ID=64500047

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020522786A Active JP7271532B2 (ja) 2017-07-07 2018-07-05 生物学的結合分子
JP2020522785A Active JP7239575B2 (ja) 2017-07-07 2018-07-05 サンプル中の自律的に活性なb細胞受容体または自律的に活性化されたb細胞受容体を認識する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020522786A Active JP7271532B2 (ja) 2017-07-07 2018-07-05 生物学的結合分子

Country Status (5)

Country Link
US (2) US11634487B2 (enExample)
EP (4) EP3424527A1 (enExample)
JP (2) JP7271532B2 (enExample)
CA (2) CA3070847A1 (enExample)
WO (2) WO2019008129A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424527A1 (de) * 2017-07-07 2019-01-09 AVA Lifescience GmbH Diagnostisches verfahren
US20220227864A1 (en) * 2019-05-02 2022-07-21 Ava Lifescience Gmbh Biological binding molecules
EP3733709A1 (de) * 2019-05-02 2020-11-04 AVA Lifescience Biologische bindemoleküle
WO2020221463A1 (de) * 2019-05-02 2020-11-05 Ava Lifescience Gmbh Verfahren zur selektion biologischer bindemoleküle
CN118613499A (zh) * 2021-08-18 2024-09-06 宾夕法尼亚大学董事会 对b细胞受体特异的嵌合抗原受体的组合物和方法
EP4476264A1 (en) 2022-02-10 2024-12-18 SinABioSolution GmbH Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof
EP4227321A1 (en) 2022-02-10 2023-08-16 AVA Lifescience GmbH Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia (cll) for use in treatment of cll
KR20250075563A (ko) * 2022-07-25 2025-05-28 시나바이오솔루션 게엠베하 만성 림프구성 백혈병의 b-세포 수용체를 표적으로 하는 인간화 키메라 항원 수용체 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
ES2741936T3 (es) * 2012-02-24 2020-02-12 Abbvie Stemcentrx Llc Anticuerpos anti-SEZ6 y procedimientos de uso
US9770504B2 (en) * 2013-05-03 2017-09-26 The Board Of Regents Of The University Of Texas System Generating peptoid vaccines
PE20160674A1 (es) * 2013-08-28 2016-07-21 Stemcentrx Inc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
EP3424527A1 (de) 2017-07-07 2019-01-09 AVA Lifescience GmbH Diagnostisches verfahren

Similar Documents

Publication Publication Date Title
JP2020527727A5 (enExample)
RU2014149332A (ru) Антитела против клаудина 18.2 для диагностики рака
JP2020526590A5 (enExample)
RU2014114172A (ru) Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
JP2020018311A5 (enExample)
JP2016505634A5 (enExample)
JP5941615B2 (ja) ヒトcxcl1タンパク質の免疫学的測定方法
RU2010148904A (ru) Антитела к интерлейкину-1альфа и способы применения
RU2013111533A (ru) Способы получения мультиспецифичных и мультивалентных антител
RU2015126533A (ru) Анти-cd47 антитела и способы их применения
PE20070183A1 (es) Anticuerpos monoclonales anti-trkb
JP2015519055A5 (enExample)
JP2007526233A5 (enExample)
JP2016512034A5 (enExample)
RU2018119366A (ru) Мыши с гуманизированной легкой цепью
JP2019523651A5 (enExample)
IL273196B2 (en) Claudin6 antibodies and methods of treating cancer
JP2011510654A5 (enExample)
RU2018137419A (ru) Связывающиеся с cd38 и pd-l1 молекулы
JP2018505681A5 (enExample)
RU2018128414A (ru) Новое psma-связывающее антитело и его применения
JP2013509878A5 (enExample)
WO2019235915A8 (en) Methods and means for attracting immune effector cells to tumor cells
CN115917061A (zh) 用于生成纳米抗体的快速单步梯度法
RU2017134043A (ru) Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью